Session ID: 

Counterfeit Pharmaceuticals Supply Chain

2:30pm - 3:30pm Wednesday, February 13
Orlando - Orange County Convention Center


In a report released in November 2017, the World Health Organization (WHO) estimated that "1 in 10 medical products circulating in low and middle-income countries is either substandard or falsified;" that includes pills, vaccines, and diagnostic kits that also impacting the U.S. health system. The counterfeit drug problem is not new but has been growing exponentially worldwide. The internet has facilitated the trafficking of fake and substandard drugs worldwide and drug shortages have accelerated the problem in the United States. Falsified and poor-quality drugs may be purchased online or in street markets, however, in developing countries, the supply chain may stretch between several countries, using ingredients from one area, manufactured in another, packaged in a third country and distributed in a fourth.  Addressing this issue includes identification of diversion/insertion points, following the API, examining import/export records and harnessing social media information.

Learning Objectives: 

  • Discuss the worldwide problem of counterfeit and fake pharmaceuticals and devices
  • Identify strategies that address the intersection of cost, quality and outcomes in the pharmaceutical supply chain
  • Integrate best practices of replicable supply chain strategies that address the use of data analytics
  • Construct and streamline supplier relationships to promote risk sharing
  • Differentiate redesign structures that support a continuum of care which manages quality and costs


Senior Principal, Healthcare Fraud,
MITRE Corporation
Global Security Director,
MERCK Pharmaceuticals


Clinical Informaticists
Government or Public Policy Professional
Supply Chain Management Professionals/Clinicans